Phase 1 proof-of-mechanism electroencephalogram biomarker study in healthy volunteers of QRL-101 to characterize the potential anti-seizure effects of QRL-101.
Latest Information Update: 23 Sep 2024
At a glance
- Drugs QRA-244 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Biomarker; Therapeutic Use
- 23 Sep 2024 New trial record